Rat liver 3a-hydroxysteroid dehydrogenase (3a-HSD) (EC 1.1.1.50) is an NAD(P)+-dependent oxidoreductase that is potently inhibited at its active site by non-steroidal anti-inflammatory drugs (NSAIDs). Initial-velocity and productinhibition studies performed in either direction at pH 7.0 are consistent with a sequential ordered Bi Bi mechanism in which pyridine nucleotide binds first and leaves last. This mechanism is supported by fluorescence titrations of the E-NADH complex, and by the failure to detect the binding of either [3H] 
INTRODUCTION
Hydroxysteroid dehydrogenases are a family of NAD(P)+-linked oxidoreductases that interconvert alcohols and ketones on the steroid nucleus and side chain in a positional and stereoselective manner (Talalay, 1963) . The mammalian enzymes are believed to play pivotal roles in the regulation of steroid hormone action (Taurog et al., 1975; Jacobi et al., 1977; Funder et al., 1988) , and 3a-hydroxysteroid dehydrogenase (3a-HSD) belongs to this group. 3a-HSD has been shown to convert the potent androgen (Sa-dihydrotestosterone) into the weak androgen (3a-androstanediol) (Scheme 1) (Dorfman & Dorfman, 1963; Liao et al., 1973) (Penning et al., 1986) . The enzyme can be purified in milligram quantities (Penning et al., 1984) , and its abundance has led to the assignment of additional functions to the rat liver enzyme. 3a-HSD displays dual pyridine nucleotide specificity (NADI and NADP+) and accounts for the major dihydrodiol dehydrogenase and aromatic ketone reductase activities present in rat liver cytosol (Penning et al., 1984) . In addition, it displays 9-, 11-and 15-hydroxyprostaglandin dehydrogenase activity . The enzyme also has the novel property of being potently inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs) in rank order of their pharmacological potencies (Penning & Talalay, 1983) , and evidence has accumulated to suggest that 3a-HSD may be an additional target for these drugs (Penning et al., 1986) . The enzyme has been crystallized for X-ray studies, and its cDNA has been cloned and sequenced (Isaacson et al., 1988; Pawlowski et al., 199 1a,b) . The deduced amino acid sequence shows 69 % sequence identity with bovine lung prostaglandin F synthase Pawlowski et al., 1991b) and further points to a role for the enzyme in the transformation of inflammatory prostanoids. In general, hydroxysteroid and hydroxyprostaglandin dehydrogenases are pyridine-nucleotide-linked enzymes which can display either ordered or random Bi Bi sequential kinetic mechanisms. Sequentially ordered Bi Bi mechanisms in which nucleotide binds first and leaves last have been described for the Abbreviations used: 3a-HSD, 3a-hydroxysteroid dehydrogenase [3a.
-hydroxysteroid: NAD(P)+ oxidoreductase (EC 1.1.1.50)]; androsterone, 5ca-androstan-3a-ol-17-one; androstanedione, 5a-androstan-3, 1 7-dione; testosterone, 1 7f-hydroxyandrost-4-en-3-one; indomethacin, 1-(pchlorobenzoyl)-5-methoxy-2-methylindol-3-ylacetic acid; NSAIDs, non-steroidal anti-inflammatory drugs; vinyl ketone, 1-(4-nitrophenyl)-2-propen- Pseudomonas testosteroni dehydrogenases displaying 3a-hydroxysteroid (Skalhegg, 1975) and 3(17),-hydroxysteroid (Levy et al., 1987) activities. In addition, rat ovarian 20a-hydroxysteroid dehydrogenase (Pongsawasdi & Anderson, 1984) and mouse liver 3cx-HSD (Hara et al., 1988) have been show to display ordered Bi Bi mechanisms. By contrast, human placental 17,f-hydroxysteroid dehydrogenase has been shown to follow a random Bi Bi sequential mechanism (Betz, 1971) . Kinetic studies on purified human placental NADI-dependent 15-hydroxyprostaglandin dehydrogenase are consistent with an ordered Bi Bi mechanism with NADI binding first (see Hansen, 1976 , for a review).
Studies from this laboratory have implied that rat liver 3a-HSD may follow a random Bi Bi kinetic mechanism. It can be inactivated by a series of bromoacetyl-steroids (Penning et al., , 1991 and bromoacetamido-NSAID analogues (Askonas et al., 1988 (Askonas et al., , 1990 in the absence of NAD+. In addition, both NADI and indomethacin (a potent NSAID) protect the enzyme against inactivation by these affinity-labelling agents. However, analysis of these protection data gave estimates of the Kd for indomethacin which were inconsistent with that determined by Dixon-plot analysis for this drug. Furthermore, the Kd values deduced for bromoacetamido-NSAIDs from inactivation experiments were also inconsistent with those obtained under initialvelocity conditions (Askonas et al., 1988) . These discrepancies could be explained by the formation of two different complexes, i.e. low-affinity binary complexes between free enzyme and the NSAIDs or their bromoacetamido analogues, and high-affinity ternary complexes between E B NADI and NSAIDs or their bromoacetamido analogues. These findings could be rationalized by a random mechanism in which the alpha and beta terms are significant, or by an ordered mechanism in which NSAIDs bind with low affinity to form abortive binary complexes with free enzyme.
Since 3a-HSD satisfies many of the criteria expected of a target enzyme for NSAIDs, it is important to document the kinetic mechanism for this enzyme and identify all the complexes through which NSAIDs may exert their inhibitory effects. Results presented here suggest that the kinetic mechanism of 3a-HSD is predominantly ordered, with pyridine nucleotide binding first and leaving last. Dead-end ternary complexes, equivalent to EB nucleotide * NSAID, are observed which can suppress the reaction in the forward or reverse direction. The formation of low-affinity E * NSAID and E B bromoacetamido-NSAID complexes is also substantiated; however, these binary complexes are dead-end complexes for which no productive analogous complex forms during the natural course of the enzyme reaction. This information has been integrated into a model of inhibition of 3a-HSD by NSAIDs and may provide additional insights into the mechanism of action of these drugs. 1-(4-Nitrophenyl)-2-propen-1-one (vinyl ketone) was synthesized as previously described (Ricigliano & Penning, 1989 ).
Preparation and assay of enzyme 3a-HSD was purified to homogeneity as previously described (Penning et al., 1984) . The final specific activity of the enzyme used in these kinetic studies was 1.93 ,umol of androsterone oxidized/min per mg under standard assay conditions [75 /cMandrosterone, 2.3 mM-NADI, 100 mM-potassium phosphate buffer, pH 7.0, and 4 % acetonitrile (v/v) in a 1.0 ml system at 25°C]. The reaction was started by the addition of enzyme, and the rate of formation of NADH (c 6270 M-1 cm-') monitored at 340 nm over 5 min using a Gilford 260 u.v.-visible recording spectrophotometer.
Analysis of kinetic data
Enzyme-kinetic data from initial-velocity, product-inhibition and dead-end-inhibition studies were fitted to the appropriate rate equation with the FORTRAN computer programs described by Cleland (1977 Cleland ( , 1979 3a-Hydroxysteroid dehydrogenase kinetic mechanism Equilibrium-dialysis studies 3a-HSD, stored in a glycerol-containing buffer (Penning et al., 1984) , was dialysed against 20 mM-potassium phosphate buffer (pH 7.0)/1 mM-EDTA/I mM-2-mercaptoethanol/5 % acetonitrile (v/v) at 4 'C. The activity of 3a-HSD was redetermined after dialysis, and the enzyme was diluted appropriately with dialysis buffer. Solutions of the radioligands were prepared daily in the above buffer. Aliquots of 3a-HSD (100 ,ul) were subjected to equilibrium dialysis against 1.0 ml of dialysis buffer in the presence of increasing concentrations of radioligand at 25 'C in the presence or absence of saturating concentrations of nucleotides. At appropriate time intervals, 10 ,ul samples were removed from the sample and diffusate and subjected to liquidscintillation counting of radioactivity. At equilibrium, triplicate measurements were taken for liquid-scintillation counting, and the enzyme concentration was re-determined. Equilibrium-dialysis experiments with indomethacin were conducted in an EMD lOiB 1/10 Equilibrium Microvolume Dialyzer apparatus (Hoefer Scientific Instruments, San Francisco, CA, U.S.A.).
Synthesis of pro-R-and pro-S-14-3HJNADH (Loewus et al., 1956) , and pro-S-[4-3H]NADH was synthesized utilizing yeast alcohol dehydrogenase (Type-A stereochemistry) (Loewus et al., 1953 t Inhibitors used were androstanedione (P), NADH (Q), indomethacin (Indo.) and 1-(4-nitrophenyl)-2-propen-l-one (vinyl ketone) (V.K.).
I Four concentrations of each unsaturating substrate were used.
of the fit) obtained with the NONCOMP program was lower than the o-value obtained with the COMP program. However, when the NONCOMP fit gave errors for the Ki term in excess of 50 % of the estimated value, it was concluded that this term was insignificant in the rate equation. In these cases it was decided that the competitive fit was the more appropriate (Cleland, 1979) . The observed patterns of product inhibition are compared with the predicted patterns for several kinetic mechanisms (Segel, 1975) in Table 2 (a). It should be noted that the closest fit of the product-inhibition patterns is to a rapid equilibrium random Bi Bi mechanism with a dead-end EAP complex.
Dead-end inhibition studies Dead-end inhibition studies were also conducted to elucidate the kinetic mechanism. Two different classes of inhibitors were chosen, NSAIDs (which are known competitive inhibitors against androsterone) (Penning et al., 1984) and the aromatic vinyl ketone [1-(4-nitrophenyl)-2-propen-l-one], which competes for, and alkylates, the NADI-binding site of 3a-HSD (Ricigliano & Penning, 1990) . As tabulated in Table 2 (b), indomethacin displays competitive inhibition against androsterone (Ki = 0.74 #M) (Fig. 2a) and uncompetitive inhibition against NADI (Ki = 0.57 4uM) (Fig. 2b) . In the reverse direction, indomethacin exhibits the same inhibition patterns. Thus, under initial-velocity conditions, the enzyme forms E.NAD(H)-indomethacin complexes. By contrast, the vinyl ketone displays apparent competitive kinetics against NADI and mixed-type kinetics versus androsterone (Ricigliano & Penning, 1990 Measurement of binary and ternary complexes on the normal kinetic path The preceding sections clearly show that product-inhibition and dead-end-inhibition studies give inconsistent results with regard to the identity of the kinetic mechanism. The productinhibition studies suggest a random Bi Bi mechanism with a dead-end EAP complex, whereas the dead-end-inhibition studies support an ordered Bi Bi mechanism. To distinguish between these alternatives, attempts were made to measure the binary complexes predicted by each mechanism. It is possible to measure the E* NADH binary complex by fluorescence titration. The Kd values obtained for the E-NADH and E* NADPH complexes by this means have been previously reported and are 160 4UM and 195 nm respectively (Ricigliano & Penning, 1990) . The value for the E-NADH complex confirms the value predicted by initialvelocity studies (Table 1 Attempts were also made to measure dead-end ternary complexes that might contribute to the kinetic mechanism.
However, no binding of [3H] androsterone to E.NADH and no binding of [3H] androstanedione to E.NAD+ could be detected under conditions of equilibrium dialysis. Thus, EAP and EBQ dead-end ternary complexes do not participate in the kinetic mechanism of 3a-HSD. These observations further negate interpreting the product-inhibition studies as supporting a rapid equilibrium random Bi Bi mechanism with the formation of a dead-end EAP complex.
Analysis of the individual rate constants for an ordered Bi Bi mechanism
The aforementioned studies support a sequential ordered Bi Bi kinetic mechanism for rat liver 3a-HSD, with nicotinamide nucleotide binding first and leaving last. By using the values obtained from the SEQUEN program in Table 1 , it was possible to calculate the individual rate constants for the mechanism (Table 3) (Segel, 1975) . These rate constants predict that the enzymic reaction is freely reversible at pH 7.0, that the binding and release of nicotinamide nucleotide is rate-limiting and that isomerization of the central complex is favoured in the forward direction. (Table 1) (Segel, 1975 The product-inhibition patterns described in Table 2 (a) can be justified by an ordered mechanism when the values of the individual rate constants are considered. At a constant concentration of androsterone, androstandione is a mixed inhibitor against NADI (no EAP), and NADH is a competitive inhibitor of NADI, as predicted by a simple ordered Bi Bi mechanism (Table 2a) . By contrast, the product-inhibition patterns observed at constant NADI concentrations are inconsistent with those predicted for a simple ordered mechanism. When androstanedione is varied against androsterone, competitivepatterns are observed at both unsaturating and saturating concentrations of NADI. An ordered Bi Bi mechanism would predict mixed patterns, but a Theorell-Chance mechanism would predict competitive product-inhibition patterns. This would suggest that, as in a Theorell-Chance mechanism, the ratelimiting step in the kinetic mechanism of 3a-HSD may be the release of NADH (Q), a suggestion substantiated by the individual rate constants (Table 3) . They reveal that steroid is released very quickly from the central complex, while the release of pyridine nucleotide may well be a rate-limiting step. These findings support the product inhibition patterns observed. Advocation of a Theorell-Chance mechanism, however, is ruled out because the criteria KA = KA, KQm = K?, k-2 > k1, and k3 > k4 (Segel, 1975) do not hold (Tables 1 and 3 ). These interpretations of the product-inhibition patterns still fail to describe why competitive inhibition patterns are observed when NADH is varied against androsterone at unsaturating fixed concentrations of NADI. This can be explained by the individual rate constants which show that NADH (k-4 = 9.31 x I05 M-1 min-') binds seven times faster than NADI (k+1 = 1.35 x 10 M-1 min-') to free enzyme at pH 7.0. Thus NADH will compete with NADI until NADI is saturating. The enzyme is then predominantly in the E A form and no inhibition by NADH is expected, and this is what is observed.
Measurement of dead-end NSAID complexes Dead-end inhibition patterns observed with indomethacin support the ordered Bi Bi mechanism and predict the formation of E B NAD(P)(H) -indomethacin complexes. By using ['4C]indomethacin as radioligand, the ternary complexes E *NAD+ _ ['4C]indomethacin and E * NADH . [14C]indomethacin were measured directly. Scatchard (1949) analysis of the binding of indomethacin to the E * NAD+ complex gave a Kd of 2.02 /M and a Bmax corresponding to 0.7 binding sites per enzyme monomer (results not shown).
During the course of the equilibrium-dialysis studies, a binary E. ['4C ]indomethacin complex was also demonstrated. The Kd for indomethacin obtained for this binary complex was 21.4 /SM, with a Bmax corresponding to 0.9 sites per enzyme monomer (results not shown). This Kd value is 10-30-fold higher than the value obtained for the E NAD+.indomethacin complex. The formation of this E . indomethacin complex by a side shunt does not contribute significantly to the inhibition patterns observed, since inhibition studies are routinely performed in the presence of NADI concentrations which are 8-fold above its Kd. Under these conditions, the enzyme is effectively trapped in its high-affinity state for indomethacin, namely E NADI. However, if NADI concentrations were to fall significantly below its Kd (288 4tM), the formation of E-indomethacin may contribute to the inhibition observed with this drug and other NSAIDs.
The formation of dead-end binary complexes is also supported by affinity-labelling studies with bromoacetoxy-steroids (Penning et al., , 1991 and bromoacetamido-NSAID analogues (Askonas et al., 1988 (Askonas et al., , 1990 The pro-R-[4-3H]NADH and the pro-S-[4-3H]NADH were used as cofactors in the enzyme-catalysed reduction of androstanedione. All reactions were carried out in a 3 ml system in 100 mM-potassium phosphate buffer, pH 6.0, and 4 % acetonitrile (v/v For simplicity, inactivation of free enzyme by the vinyl ketone is not shown (Ricigliano & Penning, 1989 (Table 4 ). These findings demonstrate that 3a-HSD is a Class A dehydrogenase in which hydride transfer occurs from the 4-pro-R position of the cofactor to the C-3 position of the steroid. Our findings support the mechanism ofhydride transfer elucidated for partially purified preparations of rat liver 3a-HSD described by Berseus & Bjorkhem (1967) and Bj6rkhem & Danielsson (1970) . In this case the prediction made by Akhtar et al. (1972) that mammalian steroid dehydrogenases which transfer hydrogen to the a-face of, the steroid molecule are Class B dehydrogenases, whereas those transferring to the fl-face are Class A dehydrogenases, applies.
Implicit in this mechanism is that the nicotinamide ring must rotate 1800 around the glycosidic bond so that the 4-pro-Rhydrogen atom can be introduced from above the plane of the steroid, forcing the resultant hydroxy group into the axial position.
Conclusions
The model for the kinetic mechanism (Scheme 2) of 3a-HSD shows it to be predominantly ordered with the nicotinamide nucleotide binding first and leaving last. In addition, it is characterized by a number of additional binary and ternary complexes (below the reaction axis). Two modes of inhibition by NSAIDs are possible. In the presence of pyridine nucleotide, NSAIDs bind to E-NAD(P)(H) complexes with high affinity to form dead-end ternary complexes, thereby depleting the amount of enzyme available for catalysis. In the absence of nicotinamide nucleotides, ligands with high affinity for the steroid-binding site, e.g. NSAIDs, can still bind to free enzyme with low affinity to form dead-end binary complexes. Free enzyme, which has low affinity for steroids and NSAIDs, can be trapped by covalent modification with bromoacetoxy-steroids and bromoacetamidoNSAIDs. Enzyme inactivated with 17fl-bromoacetoxy-5a-dihydrotestosterone retains its capacity to bind NADH by fluoresence titration, indicating that modification of the steroidbinding site has occurred (Ricigliano & Penning, 1990) . Although 3cx-Hydroxysteroid dehydrogenase kinetic mechanism this implies that binary E-steroid complexes bind nucleotide (as predicted by a random mechanism), the E' steroid complex formed by covalent modification represents a complex for which no analogous kinetically significant complex occurs.
Our model also predicts the kinetic patterns observed with the active-site-directed bromoacetoxy-steroids and bromacetamido-NSAID analogues (Scheme 2). These compounds will bind to free enzyme with low affinity and can cause enzyme inactivation. Inactivation can be retarded by both NADI and ligands that compete for the steroid-binding site, e.g. indomethacin. These data imply that formation of the binary complexes E-NADI or E * indomethacin deplete the amount of free enzyme available for inactivation. The concentrations of NADI required to obtain protection against inactivation are at or near the Kd value for the nicotinamide nucleotide, consistent with an ordered mechanism. By contrast, the concentration of indomethacin required to obtain protection is much higher than the Kd observed for the E *NAD+ * indomethacin complex, and indicates that indomethacin and the bromoacetylating agents compete for the same low-affinity form of free enzyme. In addition, initialvelocity studies with these affinity-labelling agents (in the presence of saturating NADI) indicate that these agents are competitive inhibitors with androsterone, uncompetitive inhibitors with NADI, and yield much lower K1 values for the E * NADI complex than for E alone (Penning et al., , 1991 . These data can be summarized by simply stating that the E. NADI complex has a much higher affinity for ligands that occupy the steroid-binding site than free enzyme.
The kinetic mechanism predicted in this study for 3a-HSD offers important insights into the nature of inhibition mediated by NSAIDs. Our findings suggest that NSAIDs, as well as acting as competitive inhibitors with androsterone, can effectively slow the forward and reverse reactions by forming dead-end ternary complexes equivalent to E. nucleotide . NSAID. In the absence of nucleotide, NSAIDs can inhibit the enzyme by forming non-productive binary complexes. This mode of inhibition is in contrast with that reported for the inhibition of 15-hydroxyprostaglandin dehydrogenase from bovine lung, in which indomethacin and aspirin were found to be non-competitive inhibitors with prostaglandin E2. Since aspirin has been reported to compete for the NAD+-binding site for several dehydrogenases (Einarsson et al., 1974) , it was inferred that NSAIDs inhibit 1 5-hydroxyprostaglandin dehydrogenase by binding at this site. This is not the case for 3a-HSD. Although 3a-HSD has significant sequence identity with prostaglandin F synthase Pawlowski et al., 1991b) , which is a member of the aldehyde reductase family (Hayashi et al., 1989) , NSAIDs do not potently inhibit prostaglandin F synthase or the aldehyde reductases. These studies indicate that 3a-HSD represents a novel target for NSAID inhibition and that this inhibition is mediated by the formation of binary and ternary dead-end drug complexes. This work was supported by a National Research Service Award (GM 12274 to LJA), and by National Institutes of Health Grants GM 34364 and CA 39504 to T.M.P. T.M.P. is a recipient of a Research Career Development Award from the National Cancer Institute (CA 01335). We wish to thank Dr. Mark Levy of SmithKline Beechaon for the use of their computing facilities in running the FORTRAN programs described by Cleland (1977 Cleland ( , 1979 .
